ENTL Entelos Regs

Entelos, Inc. (LSE:ENTL), a leading life sciences company building predictive computer models of human physiology and �virtual patients� for drug discovery and development, today is updating the market ahead of its pre-close period for the six-month period ended 30 June 2007. Trading for the year to date has been in line with management expectations and, as previously announced on 12 March 2007, Entelos expects that 2007 revenues will be in line with the level reported for 2006 both at the interim and year-end. The Company has good contract visibility and has cash and accounts receivables of $ 5.7 million as at 30 June 2007. Since its preliminary report on 18 April 2007, Entelos announced key developments to expand its business prospects: A broad strategic alliance with India-based Jubilant Biosys to more cost-effectively discover, in-license, and further develop a portfolio of compounds; and jointly develop and offer a complementary spectrum of in silico and traditional services from early drug discovery through phase II clinical trials. Entelos introduced its Realab� technology, a new simulation tool that enables direct web access to its state-of-the-art computer models, by launching, in collaboration with the American Diabetes Association, a Realab� website with access to the Entelos computer model of type 1 diabetes. This new technology provides scientists and clinicians an unparalleled ability to investigate the onset, progression and treatment of diabetes. In addition, James Karis, CEO of Entelos, presented the Company at healthcare-related investor conferences held in London during the month of June in order to continually promote the Company within the healthcare sector. Overall, management remains confident in the Company�s trading prospects and financial performance for the 2007 financial year. Notes to Editors About Entelos, Inc. Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies and using 'virtual patients' and 'virtual mice' to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, known as PhysioLab� platforms, to help select and develop compounds, optimize clinical trials and combination therapies, evaluate in-licensing candidates, and better position products in competitive markets. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos partners with global pharmaceutical companies and provides customized technology and research services in cardiovascular diseases, asthma, obesity, diabetes, rheumatoid arthritis, hematopoeisis (anemia), cholesterol metabolism, and skin sensitization. The company recently launched its Realab� technology, a simulation tool to provide web-based access to Entelos� powerful PhysioLab� platforms via the Internet.